Global TCR-Based Antibody 麻豆原创 Research Report 2025

Publication ID:

PB503250601

Publication Date:

March 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for TCR-Based Antibody was valued at US$ 1110 million in the year 2024 and is projected to reach a revised size of US$ 2117 million by 2031, growing at a CAGR of 9.8% during the forecast period.
TCr-Based Antibodies are used in treatment of cancer, lymphoma, myeloma, etc., these antibodies directly attack on the target and kills them.
North American market for TCR-Based Antibody is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for TCR-Based Antibody is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of TCR-Based Antibody include Adaptimmune Therapeutics, Celgene, Immunocore, Kuur Therapeutics, Lion TCR, Kite Pharma, Takara Bio, Ziopharm Oncology, GlaxoSmithKline, Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for TCR-Based Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TCR-Based Antibody.
The TCR-Based Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global TCR-Based Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the TCR-Based Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Adaptimmune Therapeutics
Celgene
Immunocore
Kuur Therapeutics
Lion TCR
Kite Pharma
Takara Bio
Ziopharm Oncology
GlaxoSmithKline
Merck
Juno Theraprutics
Segment by Type
NY-ESO-1
p53
WT-1
EBv
Others
Segment by Application
Hospitals
Specialized Clinics
Pharma and Biotech Research Laboratories.
Gene Therapy Centers
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of TCR-Based Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of TCR-Based Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 TCR-Based Antibody 麻豆原创 Overview
1.1 Product Definition
1.2 TCR-Based Antibody by Type
1.2.1 Global TCR-Based Antibody 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 NY-ESO-1
1.2.3 p53
1.2.4 WT-1
1.2.5 EBv
1.2.6 Others
1.3 TCR-Based Antibody by Application
1.3.1 Global TCR-Based Antibody 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Specialized Clinics
1.3.4 Pharma and Biotech Research Laboratories.
1.3.5 Gene Therapy Centers
1.3.6 Others
1.4 Global TCR-Based Antibody 麻豆原创 Size Estimates and Forecasts
1.4.1 Global TCR-Based Antibody Revenue 2020-2031
1.4.2 Global TCR-Based Antibody Sales 2020-2031
1.4.3 Global TCR-Based Antibody 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 TCR-Based Antibody 麻豆原创 Competition by Manufacturers
2.1 Global TCR-Based Antibody Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global TCR-Based Antibody Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global TCR-Based Antibody Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of TCR-Based Antibody, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of TCR-Based Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of TCR-Based Antibody, Product Type & Application
2.7 Global Key Manufacturers of TCR-Based Antibody, Date of Enter into This Industry
2.8 Global TCR-Based Antibody 麻豆原创 Competitive Situation and Trends
2.8.1 Global TCR-Based Antibody 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest TCR-Based Antibody Players 麻豆原创 Share by Revenue
2.8.3 Global TCR-Based Antibody 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global TCR-Based Antibody 麻豆原创 Scenario by Region
3.1 Global TCR-Based Antibody 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global TCR-Based Antibody Sales by Region: 2020-2031
3.2.1 Global TCR-Based Antibody Sales by Region: 2020-2025
3.2.2 Global TCR-Based Antibody Sales by Region: 2026-2031
3.3 Global TCR-Based Antibody Revenue by Region: 2020-2031
3.3.1 Global TCR-Based Antibody Revenue by Region: 2020-2025
3.3.2 Global TCR-Based Antibody Revenue by Region: 2026-2031
3.4 North America TCR-Based Antibody 麻豆原创 Facts & Figures by Country
3.4.1 North America TCR-Based Antibody 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America TCR-Based Antibody Sales by Country (2020-2031)
3.4.3 North America TCR-Based Antibody Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe TCR-Based Antibody 麻豆原创 Facts & Figures by Country
3.5.1 Europe TCR-Based Antibody 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe TCR-Based Antibody Sales by Country (2020-2031)
3.5.3 Europe TCR-Based Antibody Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific TCR-Based Antibody 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific TCR-Based Antibody 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific TCR-Based Antibody Sales by Region (2020-2031)
3.6.3 Asia Pacific TCR-Based Antibody Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America TCR-Based Antibody 麻豆原创 Facts & Figures by Country
3.7.1 Latin America TCR-Based Antibody 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America TCR-Based Antibody Sales by Country (2020-2031)
3.7.3 Latin America TCR-Based Antibody Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa TCR-Based Antibody 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa TCR-Based Antibody 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa TCR-Based Antibody Sales by Country (2020-2031)
3.8.3 Middle East and Africa TCR-Based Antibody Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global TCR-Based Antibody Sales by Type (2020-2031)
4.1.1 Global TCR-Based Antibody Sales by Type (2020-2025)
4.1.2 Global TCR-Based Antibody Sales by Type (2026-2031)
4.1.3 Global TCR-Based Antibody Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global TCR-Based Antibody Revenue by Type (2020-2031)
4.2.1 Global TCR-Based Antibody Revenue by Type (2020-2025)
4.2.2 Global TCR-Based Antibody Revenue by Type (2026-2031)
4.2.3 Global TCR-Based Antibody Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global TCR-Based Antibody Price by Type (2020-2031)
5 Segment by Application
5.1 Global TCR-Based Antibody Sales by Application (2020-2031)
5.1.1 Global TCR-Based Antibody Sales by Application (2020-2025)
5.1.2 Global TCR-Based Antibody Sales by Application (2026-2031)
5.1.3 Global TCR-Based Antibody Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global TCR-Based Antibody Revenue by Application (2020-2031)
5.2.1 Global TCR-Based Antibody Revenue by Application (2020-2025)
5.2.2 Global TCR-Based Antibody Revenue by Application (2026-2031)
5.2.3 Global TCR-Based Antibody Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global TCR-Based Antibody Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Adaptimmune Therapeutics
6.1.1 Adaptimmune Therapeutics Company Information
6.1.2 Adaptimmune Therapeutics Description and Business Overview
6.1.3 Adaptimmune Therapeutics TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Adaptimmune Therapeutics TCR-Based Antibody Product Portfolio
6.1.5 Adaptimmune Therapeutics Recent Developments/Updates
6.2 Celgene
6.2.1 Celgene Company Information
6.2.2 Celgene Description and Business Overview
6.2.3 Celgene TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Celgene TCR-Based Antibody Product Portfolio
6.2.5 Celgene Recent Developments/Updates
6.3 Immunocore
6.3.1 Immunocore Company Information
6.3.2 Immunocore Description and Business Overview
6.3.3 Immunocore TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Immunocore TCR-Based Antibody Product Portfolio
6.3.5 Immunocore Recent Developments/Updates
6.4 Kuur Therapeutics
6.4.1 Kuur Therapeutics Company Information
6.4.2 Kuur Therapeutics Description and Business Overview
6.4.3 Kuur Therapeutics TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Kuur Therapeutics TCR-Based Antibody Product Portfolio
6.4.5 Kuur Therapeutics Recent Developments/Updates
6.5 Lion TCR
6.5.1 Lion TCR Company Information
6.5.2 Lion TCR Description and Business Overview
6.5.3 Lion TCR TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Lion TCR TCR-Based Antibody Product Portfolio
6.5.5 Lion TCR Recent Developments/Updates
6.6 Kite Pharma
6.6.1 Kite Pharma Company Information
6.6.2 Kite Pharma Description and Business Overview
6.6.3 Kite Pharma TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Kite Pharma TCR-Based Antibody Product Portfolio
6.6.5 Kite Pharma Recent Developments/Updates
6.7 Takara Bio
6.7.1 Takara Bio Company Information
6.7.2 Takara Bio Description and Business Overview
6.7.3 Takara Bio TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Takara Bio TCR-Based Antibody Product Portfolio
6.7.5 Takara Bio Recent Developments/Updates
6.8 Ziopharm Oncology
6.8.1 Ziopharm Oncology Company Information
6.8.2 Ziopharm Oncology Description and Business Overview
6.8.3 Ziopharm Oncology TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Ziopharm Oncology TCR-Based Antibody Product Portfolio
6.8.5 Ziopharm Oncology Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Company Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.9.4 GlaxoSmithKline TCR-Based Antibody Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Merck
6.10.1 Merck Company Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Merck TCR-Based Antibody Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 Juno Theraprutics
6.11.1 Juno Theraprutics Company Information
6.11.2 Juno Theraprutics Description and Business Overview
6.11.3 Juno Theraprutics TCR-Based Antibody Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Juno Theraprutics TCR-Based Antibody Product Portfolio
6.11.5 Juno Theraprutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 TCR-Based Antibody Industry Chain Analysis
7.2 TCR-Based Antibody Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 TCR-Based Antibody Production Mode & Process Analysis
7.4 TCR-Based Antibody Sales and 麻豆原创ing
7.4.1 TCR-Based Antibody Sales Channels
7.4.2 TCR-Based Antibody Distributors
7.5 TCR-Based Antibody Customer Analysis
8 TCR-Based Antibody 麻豆原创 Dynamics
8.1 TCR-Based Antibody Industry Trends
8.2 TCR-Based Antibody 麻豆原创 Drivers
8.3 TCR-Based Antibody 麻豆原创 Challenges
8.4 TCR-Based Antibody 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Adaptimmune Therapeutics
Celgene
Immunocore
Kuur Therapeutics
Lion TCR
Kite Pharma
Takara Bio
Ziopharm Oncology
GlaxoSmithKline
Merck
Juno Theraprutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.